Últimas noticias sobre Mangoceuticals (NASDAQ:MGRX) Bolsa

Mangoceuticals

Mangoceuticals Inc focuses on developing, marketing, and selling a variety of men's wellness products and services through a telemedicine platform. The platform provides access for customers to a licensed pharmacy for online fulfillment and distribution of certain medications that may be prescribed as part of telehealth consultations, including Mango ED products.

Mangoceuticals Inc

Israeli Prime Minister Benjamin Netanyahu promised retaliation against Iran for <a href="https://www.benzinga.com/news/global/24/10/41126038/iran-attacks-israel-with-missiles-middle-east-tensions-escalates-s-p-500-stocks-bitcoin-fall-as-oil">firing over 180 missiles</a> into Israel on Tuesday. Meanwhile, Iran warned of &#8220;vast destruction&#8221; if Israel retaliates, heightening fears of a broader conflict.
What Happened: Despite the missile onslaught, no injuries were reported in Israel. However, a casualty was reported in the occupied West Bank. Iran&#8217;s foreign ministry maintained that its operation was defensive, targeting only Israeli military and security facilities.
Israel&#8217;s U.N. ambassador stated that the country will decide when and how to respond to Iran&#8217;s launch of nearly 200 ballistic missiles, emphasizing that the retaliation &#8220;will be noticed&#8221; and &#8220;painful.&#8221; He warned Iran against testing Israel&#8217;s capabilities, while stressing that Israel does not seek war but cannot ignore such attacks on its civilians, <a href="https://apnews.com/live/israel-lebanon-ground-operation-updates">reported</a> the Associated Press.
Iran&#8217;s armed forces stated that any direct intervention by Israel&#8217;s supporters against Tehran would trigger a &#8216;strong attack&#8217; from Iran on their &#8216;bases and interests&#8217; in the region, reported Reuters.
Iran&#8217;s military chief, Gen. Mohammad Bagheri, warned that Iran would strike all of Israel&#8217;s infrastructure if it takes action against Iran. He stated that the Revolutionary Guard is ready to repeat missile attacks with &#8220;multiplied intensity&#8221; and emphasized that while Iran avoided targeting civilians, it remains a feasible option, according to AP.
See Also: <a href="https://www.benzinga.com/news/24/09/41080855/kim-jong-uns-sister-says-us-making-incredible-mistake-by-giving-8b-in-military-aid-to-ukraine-should?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Kim Jong Un&#8217;s Sister Says US Making &#8216;Incredible Mistake&#8217; By Giving $8B In Military Aid To Ukraine: &#8216;Should Not&#8230;Underestimate Russia&#8217;s Serious Warning&#8217;</a>
Why It Matters: The missile attack from Iran follows a period of escalating tensions in the Middle East. Prior to the attack, the U.S. had increased its military presence in the region due to the rising tensions. 
The U.S. had <a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/24/10/41120592/iran-set-to-launch-ballistic-missile-attack-against-israel-report">also warned</a> that an attack in the region was imminent. The attack has had a significant impact on global markets, with investors reacting to the potential implications of the escalating conflict. 
Gold and oil prices <a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/24/10/41129967/market-sells-off-over-irans-attack-on-israel-port-strikes-hurricane-helene-national-se">surged following the attack</a>, with the United States Oil Fund up 3% and the SPDR Gold Trust rising 1%. Major market indexes fell, including the SPDR S&amp;P 500 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>), down 0.9%, and the Invesco QQQ Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), down 1.4%. Technology stocks were hit the hardest, while defense and oil stocks saw gains. Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) also dropped 2%.
Price Action: At the time of writing, SPY traded 0.15% lower in the after-hours session at $567.74 and QQQ was lower by almost 0.3% at $480.01.
Did You Know?
<ul>
<li>Congress Is Making Huge Investments. <a href="https://www.benzinga.com/gov-trades">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>

News

Politics

General

$BTC

Netanyahu Promises Retaliation For Missile Attack On Israel, Iran Responds By Promising 'Vast Destruction'

Top Democrats from influential House committees are urging the Drug Enforcement Administration (DEA) to expedite the process of <a href="https://www.benzinga.com/topic/cannabis-rescheduling">rescheduling cannabis.</a>
In a letter sent to Attorney General Merrick Garland and DEA Administrator Anne Milgram, Representatives Jerrold Nadler (D-NY) and Frank Pallone (D-NJ), ranking members of the Judiciary and Energy &amp; Commerce Committees respectively, stressed the need for quick action following a scientific review by the Biden administration.
See Also: <a href="https://www.benzinga.com/markets/cannabis/24/09/40938172/no-turning-back-now-cannabis-rescheduling-gains-momentum-expert-offers-timeline">&#8216;No Turning Back Now&#8217;: Cannabis Rescheduling Gains Momentum, Expert Offers Timeline</a>
According to <a href="https://www.marijuanamoment.net/top-congressional-democrats-push-dea-to-swiftly-reschedule-marijuana-and-continue-to-assess-full-legalization/">Marijuana Moment</a>, the lawmakers argue that cannabis has &#8220;less potential for abuse than other drugs&#8221; and serves an &#8220;accepted medical use in treatment.&#8221;
Their comments align with recommendations from the Department of Health and Human Services (HHS) and the Department of Justice, which have called for the reclassification of cannabis from Schedule I to Schedule III under the Controlled Substances Act (CSA).
&#8220;We value the Department of Justice's steadfast commitment to prevent the misuse and diversion of controlled substances that pose a threat to public health," Nadler and Pallone wrote.
The lawmakers applauded the Biden administration for initiating the review and urged the DEA to &#8220;swiftly complete this process and transfer marijuana to schedule III.&#8221;
<h3 class="wp-block-heading">Push For Full Descheduling</h3>
While the immediate focus is on rescheduling to Schedule III, which would loosen some federal restrictions on cannabis, the legislators also urged federal agencies to explore further reform. 
They said that &#8220;continuing to assess whether schedule IV, schedule V, or descheduling may be appropriate&#8221; could be the next step in aligning cannabis policy with evolving scientific and medical understanding. 
Descheduling, which would remove cannabis from the CSA entirely, remains a key objective for many advocates and lawmakers, including Nadler, who has previously sponsored the MORE Act &#8211; a bill that would result in full legalization.
<h3 class="wp-block-heading">Election-Year Focal Point</h3>
The timing of the lawmakers' push comes as cannabis policy increasingly takes center stage in <a href="https://www.benzinga.com/markets/cannabis/24/09/40785015/harris-campaign-accuses-trump-of-blatant-pandering-and-lying-about-his-cannabis-support-announce">U.S. election politics.</a> Both major parties are positioning themselves on the issue as the 2024 presidential election approaches. 
However, final action on the rescheduling is not expected until after November, with the DEA scheduling an administrative hearing on the matter for December 2. This hearing will allow for further input from experts and stakeholders before the agency potentially finalizes its decision.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/09/41015020/dea-boosts-psychedelics-production-for-research-cannabis-quotas-hold-steady-ahead-of-reschedulin">DEA Boosts Psychedelics Production For Research, Cannabis Quotas Hold Steady Ahead Of Rescheduling</a></li>
</ul>

Cannabis

Regulations

Markets

House Democrats Urge DEA To Speed Up Cannabis Rescheduling

ADTX

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

AREB

SOBR

Vice President&nbsp;Kamala Harris&nbsp;continues to lead former President&nbsp;Donald Trump&nbsp;in a head-to-head poll of likely voters with less than 50 days to go until the<a href="https://www.benzinga.com/topic/2024-election" target="_blank" rel="noreferrer noopener">&nbsp;2024 presidential election.</a>
What Happened: Harris maintains a five-point lead over Trump and continues to<a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40993290/trump-vs-harris-2024-election-betting-odds-show-vice-president-maintains-lead-as-race-near"> lead betting odds</a> and prediction markets against the former president with Tuesday's vice president debate a potential catalyst for the 2024 election.
A new Morning Consult poll of likely voters shows Harris' lead at five points for the week. The new <a href="https://pro.morningconsult.com/trackers/2024-presidential-election-polling?utm_source=briefing&amp;utm_medium=email&amp;utm_campaign=washington_am&amp;utm_content=100124">poll </a>shows the following results from voters, with the results from the Sept. 24 poll in parentheses:
<ul>
<li>Kamala Harris: 51% (50%)</li>
<li>Donald Trump: 46% (45%)</li>
<li>Someone Else: 2% (2%)</li>
<li>Don't Know: 2% (3%)</li>
</ul>
The poll found that 94% of Democrats backed Harris as their top pick, in line with last week&#8217;s poll. The poll also found 92% of Republicans backed Trump as their top pick, up one percentage point from last week's poll.
Independent voters selected the following as their head-to-head preference, with the results from the <a href="https://www.benzinga.com/general/politics/24/09/41016272/harris-vs-trump-2024-election-poll-shows-good-bad-news-for-each-candidate">Sept. 24 poll</a> in parentheses:
<ul>
<li>Kamala Harris:&nbsp;45% (46%)</li>
<li>Donald Trump: 44% (42%)</li>
<li>Someone Else: 5% (6%)</li>
<li>Don&#8217;t Know:&nbsp;5% (6%)</li>
</ul>
The vice president also has the edge in the 18-34 age voters demographic, leading 53% to 43%. The 10-point lead is down from last week's 12-point lead and a lead of 15-points two weeks ago. &nbsp;
Among Black voters, Harris leads by 77% to 19%.
Did You Know?
<ul>
<li>Congress Is Making Huge Investments.&nbsp;<a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent100124" target="_blank" rel="noreferrer noopener">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
Why It's Important: Trump showed gains among Black voters, Independent voters and Republican voters on the week, which is potentially bad news for Harris.
The good news for Harris and running mate Tim Walz is that the favorable ratings of the Democratic Party candidates continue to rank ahead of their counterparts.
The latest poll shows Harris with a favorable rating of 52%, down one point from last week's poll and a record high. With an unfavorable rating of 46%, Harris' net favorability is +6 pints, down from last week's record +9 points.
For comparison, Trump has a 44% favorable rating and 54% unfavorable rating, compared to 45% and 53%, respectively, in last week's poll. Trump's net favorability is -10 points, down from last week's -9 points. Trump's net favorability has often been negative during the election cycle.
When it comes to running mates, Harris' vice-presidential pick Minnesota Gov. Tim Walz ranks significantly ahead of Trump's vice-presidential pick Ohio Sen. J.D. Vance in net favorability. Walz has a net favorability of +6 while Vance has a net favorability of -9. The net favorability ratings were +9 and -10 respectively in last week's poll
Walz has a favorable rating of 45% and unfavorable rating of 39%. Vance has a favorable rating of 39% and an unfavorable rating of 48%.
Walz and Vance will<a href="https://www.benzinga.com/markets/cryptocurrency/24/09/41107455/walz-vs-vance-vp-debate-betting-odds-what-candidate-is-favored-plus-how-to-watch-likely-to"> face off Tuesday night </a>in a vice president debate that airs at 9 p.m. ET on CBS, a unit of Paramount Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PARA#NASDAQ">PARA</a>)(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PARAA#NASDAQ">PARAA</a>).
CBS News begins coverage of the debate at 8 p.m. ET on CBS and affiliate networks. The debate and coverage can also be streamed on Paramount+, CBSNews.com and YouTube. Paramount will allow simulcasting by other networks.
The debate will be 90 minutes in length with two planned four-minute commercial breaks. The candidates are not allowed to interact with their campaign teams during the commercial breaks.
Prediction market Polymarket lists a 73% chance that Walz is the winner of the debate based on YouGov surveys, which could strengthen Harris' lead in coming election polls.
Check This Out:
<ul>
<li>Lawmakers Made Huge Investments This Year. <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent100124">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a> Photos: Shutterstock<a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent100124"> </a></li>
</ul>

PARA

PARAA

Harris Vs. Trump: Vice President Leads Former President By 5 Points, Walz Favorability Rating Tops Vance Ahead Of VP Debate

Mark Spitznagel, co-founder of Universa Investments, believes the stock market is in a "Goldilocks phase" following the <a href="https://www.benzinga.com/opinion/24/10/41126981/chinas-stimulus-creates-huge-bullish-option-trades">Federal Reserve's rate cuts and China's stimulus measures.</a> After a crash last month, the market surged to new highs, but Spitznagel warns this euphoria won't last in an<a href="https://www.bloomberg.com/news/articles/2024-09-26/stock-market-s-goldilocks-zone-is-in-danger-of-an-abrupt-end?sref=TBDibEcD"> interview with Bloomberg. </a>He predicts a looming recession and believes the current rally is only temporary.
Spitznagel, known for his focus on "tail-risk" hedging, which protects against extreme, unexpected market events, says the biggest market bubble in history is about to burst. He foresees stagflation in the future, where the Fed will have to act, but it won't be enough to save the economy. Spitznagel has had success hedging through large downturns in the market, utilizing out-of-the-money put options as a way to &#8220;buy insurance&#8221; against market routs. Buying puts on the overall market through the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) or similar broad-exposure ETFs could be a way to protect against market volatility. Read Also: <a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/24/10/41129967/market-sells-off-over-irans-attack-on-israel-port-strikes-hurricane-helene-national-se">Market Sells Off Over Iran&#8217;s Attack On Israel, Port Strikes, Hurricane Helene: National Security Adviser Calls Attack &#8216;Defeated And Ineffective&#8217;</a>
Spitznagel said that while the market might continue to soar in the short term, it will soon exit the Goldilocks zone, potentially by the end of the year. With the recent &#8220;uninversion&#8221; of the yield curve, Spitznagel feels the market is now in "black swan territory." What Is A Black Swan Event: A black swan event is an unpredictable event that leads to market volatility. The COVID-19 market crash is a recent example of a black swan event. He also criticized traditional investment strategies like diversification, calling them a "big lie." He argues that modern portfolio theory has distracted investors, often making them poorer in the long run. Instead, he urges investors to focus on how their portfolios will perform in both good and bad markets.
According to Spitznagel, the key is to protect against one's own tendencies, not just market movements. Rather than fixating on what the market will do next, investors should think about how they'll react in boom and bust scenarios to avoid emotional mistakes like selling at the low and buying at the high.
Read Next: <a href="https://www.benzinga.com/news/earnings/24/10/41129610/nike-q1-earnings-revenue-miss-eps-beat-teams-energized-amid-ceo-transition-a-comeback-at-this-scale"> • Nike Q1 Earnings: Revenue Miss, EPS Beat, Teams &#8216;Energized&#8217; Amid CEO Transition — &#8216;A Comeback At This Scale Takes Time, But We See Early Wins&#8217;</a>
Photo: Shutterstock

Education

Economics

Billionaire Investor Who Predicted 2000, 2008 Crashes Says Market Euphoria Will Top Soon, Warns Of 'Black Swan Event'

Despite pouring millions into the push for adult-use cannabis legalization, Florida's cannabis market is showing signs of strain.&nbsp;
According to a recent report from <a href="https://www.benzinga.com/topic/beacon-securities-limited">Beacon Securities</a>, financial backing for the legalization campaign has surged, yet dispensary sales have slipped during the third quarter of 2024.&nbsp;
Companies like Trulieve Cannabis Corp. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TCNNF#OTC">TCNNF</a>) and Curaleaf Holdings Inc. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CURLF#OTC">CURLF</a>) are leading the charge with significant contributions, but the growing number of dispensaries and external factors, such as Hurricane Helene, have raised questions about whether the market's fundamentals justify the hype.
<ul>
<li>Get Benzinga&#8217;s exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter&nbsp;<a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. You can't afford to miss out if you&#8217;re serious about the business.</li>
</ul>
<h3 class="wp-block-heading">Turbocharged</h3>
The <a href="https://www.benzinga.com/markets/cannabis/24/09/41036799/desantis-provokes-outrage-over-taxpayer-funded-ads-linking-marijuana-legalization-to-car-crashes">Smart &amp; Safe Florida </a>campaign, responsible for spearheading the adult-use legalization efforts, received a significant financial push in September.&nbsp;
According to the report by analysts Doug Cooper, Russell Stanley and Donangelo Volpe, Trulieve Cannabis recently added $9.5 million to its contributions, while Curaleaf contributed $1 million. To date, the campaign has raised over $100 million, with more than $24 million still available. 
<h3 class="wp-block-heading">Diluted Growth</h3>
Per-dispensary sales in <a href="https://www.benzinga.com/markets/cannabis/24/09/41002710/your-cousins-in-florida-like-their-weed-why-hispanic-voters-could-tip-the-scale-for-cannabis-wil">Florida</a> showed signs of softening during Q3, impacted by an increasing number of dispensaries and temporary disruptions like Hurricane Helene.&nbsp;
The state saw a 4% quarter-over-quarter (q/q) rise in dispensaries, with nine companies adding a total of 26 new locations.&nbsp;
According to the report, Trulieve alone accounted for 12 of these openings.&nbsp;
Overall, flower sales volume in the state increased 3% q/q, while oil-based product sales dipped 1%, with both categories showing slower growth compared to the previous quarter.
On a per-dispensary basis, flower sales volumes slipped 1% q/q, while oil-based product sales fell 5%.&nbsp;
These figures likely reflect the increased competition from <a href="https://www.benzinga.com/markets/cannabis/24/09/40990665/cannabis-sales-bloom-in-first-north-carolina-weed-store-marijuana-footprint-in-florida-grows-as-">new dispensaries</a> and effect of storm-related closures.
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/09/40774795/trump-says-hell-reschedule-cannabis-if-elected-backs-marijuana-banking-reform-and-floridas-amend">Trump Says He&#8217;ll Reschedule Cannabis If Elected, Backs Marijuana Banking Reform And Florida&#8217;s Amendment</a>
<h3 class="wp-block-heading">Top Players See Mixed Results&nbsp;</h3>
Trulieve, the dominant player in <a href="https://www.benzinga.com/markets/cannabis/24/09/40969689/desantis-urges-gop-to-oppose-cannabis-legalization-as-party-splits-over-trump-marijuana-endorsem">Florida</a>, maintained its leadership position despite mixed results in both product categories. Its flower sales increased by 1% q/q, although the company lost 68 basis points (bps) in market share, now standing at 38%. In the oil-based product category, Trulieve&#8217;s sales remained flat, but it gained 50 bps in market share, increasing its lead to 31%.
Curaleaf, the second-largest operator in Florida, reported a strong 11% rise in flower sales volumes, boosting its market share by 79 bps to 10%. However, its oil-based product sales fell 2%, though it retained its second-place ranking with a 13% market share despite a slight loss of share.
Verano Holdings Corp. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/VRNOF#OTC">VRNOF</a>) had flat flower sales following sequential declines in Q1 and Q2, which were attributed to capacity upgrades. The company's market share in flower sales slipped by 19 bps, landing at 7%, keeping its third-place ranking. Verano's oil-based product sales dropped 8%, reducing its share by 68 bps to 9%.
Ayr Wellness Inc. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/AYRWF#OTC">AYRWF</a>) experienced strong growth in flower sales, up 12% q/q, which increased its <a href="https://www.benzinga.com/markets/cannabis/24/09/40753011/ayr-wellness-conditional-approval-for-medical-marijuana-operations-in-virginia-what-it-means-for">market share</a> by 51 bps to over 6%, ranking fourth in the state. However, its oil-based product sales declined 7%, dropping its share by 72 bps, though it maintained its third-place position with a 12% market share.
<h3 class="wp-block-heading">Smaller Players </h3>
<ul>
<li>Cresco Labs Inc. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CRLBF#OTC">CRLBF</a>) saw solid growth in both product categories, with flower sales volumes rising 7% q/q, raising its market share by 20 bps to 5%. The company&#8217;s oil-based product sales increased 6%, adding 23 bps in market share, taking it up to 4%.</li>
</ul>
<ul>
<li>Green Thumb Industries Inc. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/GTBIF#OTC">GTBIF</a>) posted mixed results, with flower sales declining by 18% q/q, lowering its market share by 45 bps to 2%. However, its oil-based product sales surged by 26%, adding 48 bps to its market share, also reaching 2%.</li>
</ul>
<ul>
<li>Planet 13 Holdings Inc. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/PLNHF#OTC">PLNHF</a>) managed to hold its ground in the oil-based products segment, with market share flat at 2% despite a 2% sales decline. However, the company's flower sales fell 12%, reducing its market share by 47 bps to just under 3%.</li>
</ul>
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/09/40712816/what-trump-learned-about-marijuana-that-desantis-did-not-and-why-the-gop-might-become-weed-frien">What Trump Learned About Marijuana That DeSantis Did Not And Why The GOP Might Become Weed-Friendly</a>
<h3 class="wp-block-heading">Florida's $100M Bet: What's At Stake</h3>
With adult-use cannabis legalization on the horizon through Amendment 3, Florida's market is set to see significant changes. According to <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38470560/landing-in-floridas-cannabis-market-legal-adult-use-marijuana-could-yield-874m-in-2">BDSA data</a>, total cannabis sales in Florida are projected to grow at a 12% compound annual growth rate (CAGR) from 2023 to 2028, reaching $4.5 billion by the end of that period.
However, legislative uncertainties surrounding the expansion of adult-use licenses add unpredictability to the market, with over 600 dispensaries already in operation and medical cannabis sales hitting $2.6 billion in 2023.
<h3 class="wp-block-heading">Hype-Worthy?</h3>
Pablo Zuanic&#8216;s analysis paints an optimistic picture for Florida's cannabis market, predicting a $6 billion valuation and significant growth for operators like Cansortium and AYR Wellness<a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38037571/floridas-6b-cannabis-market-anticipates-400-growth-following-court-decision-allowin"> if adult-use legalization passes in November 2024</a>.&nbsp;
Zuanic forecasts up to 400% growth for AYR and substantial upside for other major players, highlighting the potential market explosion. However, when compared to the recent Beacon Securities report, which shows slipping per-dispensary sales and slowing growth, the question remains whether the market fundamentals can sustain this anticipated boom.&nbsp;
Read Next: <a href="https://www.benzinga.com/markets/cannabis/24/09/40879364/young-republicans-break-ranks-to-back-cannabis-legalization-is-the-gop-ready-for-a-shift-in-the-">Young Republicans Break Ranks To Back Cannabis Legalization &#8211; Is The GOP Ready For A Shift In The Status Quo?</a>

Analyst Color

Market Summary

Retail Sales

Legal

Analyst Ratings

AYRWF

CRLBF

CURALEAF HLDGS INC by Curaleaf Hldgs Inc.

CURLF

GTBIF

PLNHF

TCNNF

VRNOF

Slipping Weed Sales In Florida's Market: Is This $100M Bet Really Worth The Hype?

Marijuana Pepsi Vandyck has spent her life embracing a name that has drawn attention, often unwanted, and most always raising eyebrows.
Marijuana was given the name by her mother who was convinced it would provide notoriety and "take her around the world." What the name did was put her in the position of having to answer a million questions and fend off judgment.
Her parents were of the post-Woodstock era when cannabis was coming into its own across the country. "And they would cool off with a Pepsi," Marijuana's aunt,&nbsp;Mayetta Jackson told the <a href="http://archive.jsonline.com/news/milwaukee/40874017.html/" target="_blank" rel="noreferrer noopener">Journal-Sentinel</a>. "I thought it was crazy, but they were such fun-loving people that it suited them." Marijuana's sisters have relatively common names,&nbsp;Kimberly&nbsp;and&nbsp;Robin.
Despite the challenges, Marijuana Pepsi says she&#8217;s proud of her name and never considered changing it, <a href="https://nypost.com/2024/10/01/lifestyle/woman-named-marijuana-pepsi-from-birth-will-never-change-her-name/">wrote</a> the New York Post. Until she was about 10 years old, she thought &#8220;Marijuana was just a beautiful name.&#8221; But when she moved to a new city, she became keenly aware that her name was different.
<h1 class="wp-block-heading">Got A Nickname? Black Names In White Classrooms</h1>
"When people find out my name, they ask my nickname instead. I tell them if calling me Marijuana isn't comfortable, they can call me Dr. Vandyck." 
Indeed, Marijuana, who married Fredrick Vandyck in 2017, earned a Ph.D. in higher education leadership from Cardinal Stritch University in 2019. Her dissertation topic was "Black Names in White Classrooms: Teacher Behaviors and Student Perceptions," which looked at the effects of unique names on the educational experiences of Black students. 
Her research found that students with distinctly Black names were subject to disrespect, stereotypes and low academic and behavioral expectations. Marijuana said her own name elicited the strongest reactions from white teachers.
&#8220;A lot of other people were thinking [my mom] was smoking marijuana and drinking Pepsi,&#8221; she <a href="https://www.npr.org/2019/06/21/734839666/dr-marijuana-pepsi-wont-change-her-name-to-make-other-people-happy">told</a> NPR, neither of which was the case. &#8220;In the black community, we&#8217;re used to having names that are more cultural.&#8221;
Marijuana works at the Community College of Baltimore County, where she uses her platform to promote positive educational experiences and challenge societal norms around identity and expectations. She is also the founder and executive director of&nbsp;Action As Empowerment&nbsp;Consulting &amp; Solutions, LLC. 
People often assume, again wrongly, that she consumes weed or drinks a lot of Pepsi. In fact, she does neither and never has. 
And when weed companies come calling with offers for promotional opportunities, she declines.
"I do get hit up by marijuana companies, but I wouldn't do anything with them unless it was centered around education,&#8221; Marijuana Pepsi said.
Photo: Courtesy Action As Empowerment

Marijuana Pepsi Has Always Been Proud Of Her Name, More So Now With This Honorific: 'Doctor'

Investment manager fund Chicago Atlantic recently <a href="https://www.businesswire.com/news/home/20241001828224/en/Chicago-Atlantic-and-Silver-Spike-Close-Loan-Portfolio-Acquisition-and-Joint-Venture-Transactions">acquired</a> Silver Spike Investment Corp. (NASDAD: SSIC), the only SEC-approved business development company (BDC) focused on lending to the <a href="https://www.benzinga.com/cannabis">cannabis industry</a>.
As a result, Silver Spike has been renamed Chicago Atlantic BDC, Inc., and its ticker symbol will change to $LIEN on October 2, 2024. Chicago Atlantic originates senior secured loans to state-licensed cannabis operators and has consistently traded at a premium.=
"Chicago Atlantic seeks to capitalize on opportunities in private markets by providing debt capital to lower middle-market companies, typically non-sponsor, and unique industries facing structural reasons for an insufficient supply of capital," said the company&#8217;s new CEO, Andreas Bodmeier.
<h3 class="wp-block-heading">Significant Timing For Cannabis Investors</h3>
The acquisition comes at a critical moment for the cannabis industry, as both <a href="https://www.benzinga.com/markets/cannabis/24/09/40677600/harris-campaign-slams-donald-trump-over-cannabis-shift-calls-it-brazen-flip-flop">presidential candidates </a>are signaling support for marijuana reform, rescheduling of cannabis could boost cash flow in the sector. This shift will likely benefit the company's cannabis-focused lending platform.
"We are excited about the prospects for further growth within our core activity of providing capital to high-quality operators within the cannabis ecosystem,&#8221; said Scott Gordon, executive chairman and co-chief Investment Officer. &#8220;As one of the largest direct lenders to the sector, we see significant potential to continue playing an important role in shaping the flow of much-needed debt financing to the industry."
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/06/39320509/hedge-fund-settles-at-2-25m-with-sec-for-exposed-short-seller-deal-2-cannabis-stocks-affected">Hedge Fund Settles At $2.25M With SEC For Exposed Short Seller Deal, 2 Cannabis Stocks Affected</a>
<h3 class="wp-block-heading">Unique Market Opportunity</h3>
The merger also creates a unique opportunity for investors. 
Chicago Atlantic BDC allows access to credit alpha that differs from traditional BDCs or private credit funds. Bodmeier pointed out the value of this position, noting that "the rapidly growing cannabis sector represents a compelling example of an industry where capital is in short supply."
This acquisition and joint venture between Chicago Atlantic and Silver Spike are expected to strengthen the company's role in providing financing solutions to cannabis operators.
<ul>
<li>Read Next: <a href="https://www.benzinga.com/markets/cannabis/24/08/40506425/new-sec-filings-reveal-major-risks-in-cannabis-etfs-following-recent-volatility-but-theres-still">New SEC Filings Reveal Risks In Cannabis ETFs Following Recent Volatility — But There&#8217;s Still Room For Optimism </a></li>
</ul>
Cover: AI Generated Image

REIT

Press Releases

Real Estate

SSIC

SEC-Approved Cannabis Lender Acquired By Investment Giant, Changes Ticker To $LIEN

The Company&rsquo;s board of directors approved such action on August 22, 2024, and the affected employees were informed of this action beginning on October 1, 2024.
The suspension of the Company&rsquo;s operations in China will involve declaring the Company&rsquo;s wholly-owned subsidiary dormant, which is a legal entity status available under current China law. Under this legal entity status, operational activities cease for a time period not to exceed three years.
By pursuing this entity status, the Company will initiate a project to suspend current operational activities, which are estimated to cease on or before December 31, 2024. Suspension activities include disposal and shipment of certain equipment in China, the termination of 2 employees and related benefit costs, and legal entity filing fees.
In connection with this action, the Company estimates that it will incur approximately $400,000 to $500,000 of costs, primarily consisting of employee termination payments, as well as equipment disposal and shipment and legal filing fees. The Company expects that these charges will be incurred primarily in the fourth quarter of 2024.

CLIR

ClearSign Suspends Operations In China Due To Delayed Progress On Commercialization Of Its Products And As Part Of Efforts To Align Strategic Priorities And To Reduce Operating Costs - Filing

Coinciding with this decision, Kate O&rsquo;Brian, President, Scripps News, will be leaving the Company at the end of the year.
Scripps News will no longer broadcast over the air, although it will remain on streaming and digital platforms with weekday live coverage from the field. As a result of these changes, the Company expects to eliminate more than 200 jobs. We expect approximately 50 Scripps News staff members will remain to report for our local news audiences and produce streaming and digital content, all under the Scripps News brand.

E.W. Scripps To Wind Down Scripps News' 24/7 National Network Programming After November 15; To Eliminate More Than 200 Jobs - Filing

Management

SandRidge Energy Names Vincent Intrieri As Chairman, Effective October 1; Jonathan Frates To Step Down As Chairman Today To Transition To The Role Of Executive Vice President And CFO, Effective October 21

Updated Fiscal 2025&nbsp;Outlook
<ul>
<li>Reducing GAAP net income target to&nbsp;$395 million&nbsp;to&nbsp;$445 million, and Diluted EPS target to&nbsp;$2.70&nbsp;to&nbsp;$3.15</li>
<li>Targeting low-end of target ranges of Adjusted EBITDA(1)&nbsp;of&nbsp;$1,380&nbsp;million to&nbsp;$1,480&nbsp;million</li>
<li>Reducing Adjusted Net Income&nbsp;target to&nbsp;$600 million&nbsp;to&nbsp;$615 million&nbsp;and Adjusted Diluted EPS&nbsp;target to&nbsp;$4.15&nbsp;to&nbsp;$4.35</li>
<li>Reducing capital expenditures target by&nbsp;$100 million&nbsp;to&nbsp;$750 million</li>
</ul>

Guidance

Lamb Weston Reaffirms FY25 Net Sales Outlook Of $6.6B - $6.8B (Est $6.615B), Revises Adjusted EPS Target To $4.15 - $4.35 (Est $4.48)

Futu Holdings Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FUTU#NASDAQ">FUTU</a>) shares continued higher after-hours on Tuesday as shares of China-based companies rose following additional stimulus measures aimed at boosting China's economy were <a href="https://www.benzinga.com/news/24/09/41097864/china-stocks-jump-as-stimulus-optimism-mounts-whats-going-on">announced over the weekend. </a>
The Details: China announced additional stimulus measures including lower mortgage rates and looser real estate purchase restrictions over the weekend. The new measures follow a package of extensive stimulus measures including lower interest rates and additional liquidity for its banking system announced last week. 
Read Next: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/41071876/mojo-is-back-at-tesla-says-tech-analyst-dan-ives-ahead-of-q3-deliveries">Tesla &#8216;Mojo Is Back,&#8217; Tech Analyst Dan Ives Says Ahead Of Q3 Deliveries</a>
Additionally, China's central bank will set up a swap facility that would give non-bank financial institutions access to at least $71 billion (500 billion yuan) in funding to buy shares, in an effort aimed at stabilizing China's stock market. 
Futu, which operates trading platforms in China and around the world, may benefit from increased capital in the markets resulting from the intensive stimulus package. Futu shares have gained more than 40% over the past five days as investors pile into U.S.-traded Chinese stocks.&nbsp;
FUTU Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Futu Holdings shares ended Tuesday&#8217;s session up 12.43% at $107.54; shares are up 0.65% at $108.24 in after-hours trading.
Read Also:
<ul>
<li><a href="https://www.benzinga.com/news/24/09/41070564/amazon-prime-day-data-insights-before-october-event-apple-purchases-up-22-celsius-tops-grocery-categ">Amazon Prime Day Data Insights Before October Event: Apple Purchases Up 22%, Celsius Tops Grocery Category</a></li>
</ul>
Photo: Shutterstock

Global

Movers

FUTU

What's Going On With Futu Holdings' Stock?

Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) has outperformed the market over the past 20 years by 3.1% on an annualized basis producing an average annual return of 11.54%. Currently, Gilead Sciences has a market capitalization of $104.43 billion. 
Buying $1000 In GILD: If an investor had bought $1000 of GILD stock 20 years ago, it would be worth $8,831.14 today based on a price of $83.88 for GILD at the time of writing.
<h3>Gilead Sciences's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727818474_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

GILD

$1000 Invested In This Stock 20 Years Ago Would Be Worth $8,800 Today

Norfolk Southern (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NSC#NYSE">NSC</a>) has outperformed the market over the past 20 years by 4.85% on an annualized basis producing an average annual return of 13.29%. Currently, Norfolk Southern has a market capitalization of $56.10 billion. 
Buying $1000 In NSC: If an investor had bought $1000 of NSC stock 20 years ago, it would be worth $12,247.78 today based on a price of $248.14 for NSC at the time of writing.
<h3>Norfolk Southern's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727818469_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $1000 In This Stock 20 Years Ago, You Would Have $12,000 Today

Restructuring Plan
<ul>
<li>Restructuring actions expected to generate approximately&nbsp;$55 million&nbsp;of pre-tax cost savings in fiscal 2025 and a&nbsp;$100 million&nbsp;reduction in capital expenditures in fiscal 2025</li>
<li>Key actions include closing Connell, Washington facility, temporarily curtailing production lines and schedules in North America, reducing approximately&nbsp;4%&nbsp;of global workforce, and eliminating unfilled job positions</li>
<li>Expected to record total estimated pre-tax charges of&nbsp;$200 million&nbsp;to&nbsp;$250 million</li>
</ul>

Lamb Weston Plans Reducing Approximately 4% Of Global Workforce, And Eliminating Unfilled Job Positions

Lamb Weston Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LW#NYSE">LW</a>) reported quarterly earnings of $0.73 per share which beat the analyst consensus estimate of $0.71 by 2.82 percent. The company reported quarterly sales of $1.65 billion which beat the analyst consensus estimate of $1.56 billion by 6.34 percent. This is a 0.66 percent decrease over sales of $1.67 billion the same period last year.

Earnings

Earnings Beats

Lamb Weston Q1 2025 Adj EPS $0.73 Beats $0.71 Estimate, Sales $1.65B Beat $1.56B Estimate

ATCH

AtlasClear Files With SEC  A Notification Of Late Filing For Its Transition Report

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Pre-market stock movers are worth checking out on Wednesday as we offer up all the latest news sending shares higher and lower this morning!



Moving stocks this morning are continued rallies, heavy trading, clinical trials and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Akoustis Technologies (NASDAQ:<a href="https://investorplace.com/stock-quotes/akts-stock-quote/">AKTS</a>) stock is rocketing more than 142% alongside heavy pre-market trading.</li>



<li>Mustang Bio (NASDAQ:<a href="https://investorplace.com/stock-quotes/mbio-stock-quote/">MBIO</a>) shares are soaring over 82% with strong early morning trading.</li>



<li>MGO Global (NASDAQ:<a href="https://investorplace.com/stock-quotes/mgol-stock-quote/">MGOL</a>) stock is surging more than 68% as it <a href="https://investorplace.com/2024/05/why-is-mgo-global-mgol-stock-up-106-today/">continues to rally</a>.</li>



<li>Barnes &amp; Noble Education (NYSE:<a href="https://investorplace.com/stock-quotes/bned-stock-quote/">BNED</a>) shares are gaining close to 54% as its <a href="https://investorplace.com/2024/05/what-is-going-on-with-barnes-noble-education-bned-stock-today/">rally yesterday continues</a>.</li>



<li>Rezolute (NASDAQ:<a href="https://investorplace.com/stock-quotes/rzlt-stock-quote/">RZLT</a>) stock is rising over 31% after <a href="https://www.nasdaq.com/press-release/rezolute-reports-positive-topline-results-from-phase-2-proof-of-concept-study-of">releasing positive study results</a>.</li>



<li>DermTech (NASDAQ:<a href="https://investorplace.com/stock-quotes/dmtk-stock-quote/">DMTK</a>) shares are increasing more than 28% with heavy trading this morning.</li>



<li>Mangoceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/mgrx-stock-quote/">MGRX</a>) stock is heading over 22% higher after <a href="https://investorplace.com/2024/05/why-is-mangoceuticals-mgrx-stock-up-130-today/">rallying yesterday too</a>.</li>



<li>VS Media (NASDAQ:<a href="https://investorplace.com/stock-quotes/vsme-stock-quote/">VSME</a>) shares are climbing more than 19% without any clear news this morning.</li>



<li>Eupraxia Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/eprx-stock-quote/">EPRX</a>) stock is jumping over 15% on <a href="https://www.marketwatch.com/story/eupraxia-pharmaceuticals-shares-pop-after-new-trial-data-4e20f13b?mod=newsviewer_click">new drug trial data</a>.</li>



<li>CCSC Technology (NASDAQ:<a href="https://investorplace.com/stock-quotes/cctg-stock-quote/">CCTG</a>) shares are up more than 15% despite a lack of news.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Crown ElectroKinetics (NASDAQ:<a href="https://investorplace.com/stock-quotes/crkn-stock-quote/">CRKN</a>) stock is diving over 24% after <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318339015&amp;type=PDF&amp;symbol=CRKN&amp;cdn=9fd92bcd34f4f2180730286b7103ecb0&amp;companyName=Crown+Electrokinetics+Corp.&amp;formType=DEF+14A&amp;formDescription=Other+definitive+proxy+statements&amp;dateFiled=2024-05-21">announcing shareholder meeting plans</a>.</li>



<li>Edible Garden (NASDAQ:<a href="https://investorplace.com/stock-quotes/edbl-stock-quote/">EDBL</a>) shares are tumbling more than 24% without any apparent news to report.</li>



<li>Euronav (NYSE:<a href="https://investorplace.com/stock-quotes/eurn-stock-quote/">EURN</a>) stock is taking an over 20% beating on no clear news this morning.</li>



<li>Sintx Technologies (NASDAQ:<a href="https://investorplace.com/stock-quotes/sint-stock-quote/">SINT</a>) shares are sliding nearly 19% on Wednesday morning.</li>



<li>FLJ Group (NASDAQ:<a href="https://investorplace.com/stock-quotes/flj-stock-quote/">FLJ</a>) stock is dropping more than 16% this morning.</li>



<li>Cheetah Net Supply Chain (NASDAQ:<a href="https://investorplace.com/stock-quotes/ctnt-stock-quote/">CTNT</a>) shares are falling over 16% as they continue to drop.</li>



<li>LifeStance Health (NASDAQ:<a href="https://investorplace.com/stock-quotes/lfst-stock-quote/">LFST</a>) stock is decreasing more than 15% after <a href="https://www.nasdaq.com/press-release/lifestance-health-group-announces-pricing-of-secondary-public-offering-2024-05-21">pricing a secondary offering</a>.</li>



<li>Chijet Motor (NASDAQ:<a href="https://investorplace.com/stock-quotes/cjet-stock-quote/">CJET</a>) shares are dipping over 15% after rallying yesterday.</li>



<li>Meta Data (NYSE:<a href="https://investorplace.com/stock-quotes/aiu-stock-quote/">AIU</a>) stock is slipping more than 15% today.</li>



<li>Vicarious Surgical (NYSE:<a href="https://investorplace.com/stock-quotes/rbot-stock-quote/">RBOT</a>) shares close out our pre-market stock movers down over 14% on a <a href="https://www.investing.com/news/company-news/vicarious-surgical-ceo-sells-shares-worth-9506-93CH-3450561">CEO share sale</a>.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/05/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-wednesday-may-22nd/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Pre-market stock movers are a hot topic as investors return to trading on Tuesday following the long holiday weekend!



Moving stocks this morning are new agreements, clinical trial data, an upcoming delisting and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Sharps Technology (NASDAQ:<a href="https://investorplace.com/stock-quotes/stss-stock-quote/">STSS</a>) stock is rocketing more than 241% on a new <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318349222&amp;type=PDF&amp;symbol=STSS&amp;cdn=f5cb046a5031c2185959eb57ffce2eb2&amp;companyName=Sharps+Technology+Inc.&amp;formType=8-K&amp;formDescription=Current+report+pursuant+to+Section+13+or+15%28d%29&amp;dateFiled=2024-05-24">five-year purchase agreement</a>.</li>



<li>Insmed (NASDAQ:<a href="https://investorplace.com/stock-quotes/insm-stock-quote/">INSM</a>) shares are soaring over 140% alongside <a href="https://www.nasdaq.com/press-release/insmed-announces-positive-topline-results-from-landmark-aspen-study-of-brensocatib-in">positive clinical trial results</a>.</li>



<li>Calliditas Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/calt-stock-quote/">CALT</a>) stock is surging more than 70% after <a href="https://www.nasdaq.com/press-release/statement-by-the-board-of-directors-of-calliditas-therapeutics-ab-publ-in-relation-to">responding to a public offer</a>.</li>



<li>Yoshitsu (NASDAQ:<a href="https://investorplace.com/stock-quotes/tklf-stock-quote/">TKLF</a>) shares are increasing 41% with heavy pre-market trading.</li>



<li>Oblong (NASDAQ:<a href="https://investorplace.com/stock-quotes/oblg-stock-quote/">OBLG</a>) stock is gaining over 31% with strong early morning trading.</li>



<li>GameStop (NYSE:<a href="https://investorplace.com/stock-quotes/gme-stock-quote/">GME</a>) shares are rising more than 24% on a <a href="https://www.cnbc.com/2024/05/28/gamestop-shares-rise-21percent-in-early-trade-after-completing-stock-sale.html">$933 million stock sale</a>.</li>



<li>Nukkleus (NASDAQ:<a href="https://investorplace.com/stock-quotes/nukk-stock-quote/">NUKK</a>) stock is climbing over 22% without any clear news this morning.</li>



<li>Crown ElectroKinetics (NASDAQ:<a href="https://investorplace.com/stock-quotes/crkn-stock-quote/">CRKN</a>) shares are jumping more than 20% on Tuesday morning.</li>



<li>Nano Nuclear Energy (NASDAQ:<a href="https://investorplace.com/stock-quotes/nne-stock-quote/">NNE</a>) stock is getting an over 19% boost despite a lack of news.</li>



<li>Better Home &amp; Finance (NASDAQ:<a href="https://investorplace.com/stock-quotes/betr-stock-quote/">BETR</a>) shares are up more than 18% this morning.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Marpai (NASDAQ:<a href="https://investorplace.com/stock-quotes/mrai-stock-quote/">MRAI</a>) stock is plummeting over 39% <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318348962&amp;type=PDF&amp;symbol=MRAI&amp;cdn=1e0f606c4ec7f3739a338fa51b218460&amp;companyName=Marpai+Inc.&amp;formType=8-K&amp;formDescription=Current+report+pursuant+to+Section+13+or+15%28d%29&amp;dateFiled=2024-05-24">ahead of its delisting</a>.</li>



<li>Innovative Eyewear (NASDAQ:<a href="https://investorplace.com/stock-quotes/lucy-stock-quote/">LUCY</a>) shares are diving more than 34% without any obivous news to report.</li>



<li>Paranovus Enter (NASDAQ:<a href="https://investorplace.com/stock-quotes/pavs-stock-quote/">PAVS</a>) stock is taking an over 18% beating despite a lack of news on Tuesday morning.</li>



<li>Digital Brands Group (NASDAQ:<a href="https://investorplace.com/stock-quotes/dbgi-stock-quote/">DBGI</a>) shares are tumbling more than 14% without any recent news.</li>



<li>P3 Health Partners (NASDAQ:<a href="https://investorplace.com/stock-quotes/piii-stock-quote/">PIII</a>) stock is dropping over 14% after <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318349348&amp;type=PDF&amp;symbol=PIII&amp;cdn=0f389269475ab675a1f11c8cb0e7031c&amp;companyName=P3+Health+Partners+Inc.&amp;formType=8-K&amp;formDescription=Current+report+pursuant+to+Section+13+or+15%28d%29&amp;dateFiled=2024-05-24">issuing shares and warrants to institutional investors</a>.</li>



<li>TransCode Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/rnaz-stock-quote/">RNAZ</a>) shares are falling close to 14% on Tuesday morning.</li>



<li>Netcapital (NASDAQ:<a href="https://investorplace.com/stock-quotes/ncpl-stock-quote/">NCPL</a>) stock is decreasing more than 13% after announcing <a href="https://www.nasdaq.com/press-release/netcapital-announces-exercise-of-warrants-for-%242.2-million-gross-proceeds-2024-05-24">an exercise of warrants</a>.</li>



<li>Mangoceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/mgrx-stock-quote/">MGRX</a>) shares are slipping almost 13% today.</li>



<li>Akanda (NASDAQ:<a href="https://investorplace.com/stock-quotes/akan-stock-quote/">AKAN</a>) stock is dipping nearly 13% on Tuesday.</li>



<li>BriaCell Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/bctx-stock-quote/">BCTX</a>) shares close out our pre-market stock movers down over 11% this morning.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/05/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-tuesday-may-28th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

Mangoceuticals stock rallies on Japanese patent allowance

Mangoceuticals, Inc. (MGRX) has issued an update. Mangoceuticals, Inc. has engaged a consultant with 192,308 shares of restricted stock and additio...

Mangoceuticals Incentivizes Team with Equity Rewards

MangoRx gets notice of acceptance for patent application in Australia

MangoRx signs partnership for expansion into Asia Pacific, China and Latin America

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Mangoceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/mgrx-stock-quote/">MGRX</a>) just reported results for the second quarter of 2024.<ul><li>Mangoceuticals reported earnings per share of -9 cents.</li><li>The company reported revenue of $163,163.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/mgrx-stock-earnings-mangoceuticals-for-q2-of-2024/">MGRX Stock Earnings: Mangoceuticals Reported Results for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

MGRX Stock Earnings: Mangoceuticals Reported Results for Q2 2024

Mangoceuticals reports 1H results

Mangoceuticals files to sell 16.17M shares of common stock for holders

Mangoceuticals, Inc. (MGRX) has shared an announcement. On August 22, 2024, a company successfully completed a partial sale of its Series B Preferr...

Mangoceuticals Raises Capital and Boosts CEO Perks

AKAN

AKTS

BCTX

BETR

BNED

CALT

CCTG

CJET

CRKN

CTNT

DBGI

DMTK

EDBL

EPRX

EURN

INSM

LFST

LUCY

MBIO

MGOL

MGRX

MRAI

NCPL

NUKK

OBLG

PAVS

PIII

RBOT

RNAZ

RZLT

SINT

STSS

TKLF

VSME

Screenshot 2024-09-25 at 8.34.28 PM

Health Care

Interview

Men&#39;s Telehealth Company&#39;s Plans To Change Men&#39;s Wellness

Screenshot 2024-09-04 at 5.36.44 PM

Biotech

Hims & Hers Health, Inc. Class A Common Stock

HIMS

Prescribing The Future: How MangoRx Is Shaking Up Telemedicine With A Fresh Platform

Screenshot 2024-07-24 at 5.47.14 PM

Emerging Markets

This Men&#39;s Telehealth Company Has A Unique Take On Telehealth And Products

Screenshot 2024-07-17 at 5.41.58 PM

Say Goodbye To Inconvenient TRT: Meet The Game-Changing Oral Testosterone Treatment - PRIME By MangoRx

Screenshot 2024-07-09 at 1.59.17 PM

Erectile Function Vs Erectile Dysfunction: How MangoRx&#39;s (NASDAQ: MGRX) Product Sets Itself Apart And Caters To A Large Market (Pun Intended)

MangoRx Receives Certificate of Grant in India for its Respiratory Illness and Preventive Care Technology Patent

MangoRx Reports 1,685% Increase in Shareholders' Equity From December 31, 2023, to $13.8MM, and 56% Increase in Year-Over-Year Revenue for First Half of 2024

MangoRx Receives Request for Proposal (RFP) From ISFLST for New Male Enhancement Product Exclusive for the Asian Market

MangoRx (MGRX) Shaping the Future of Men's Health with Global Expansion and Innovative Product Launches

Mangoceuticals ($MGRX) Expands Reach: Launches New Hair Growth Product 'grow' And Strengthens Presence In Latin America With Mangorx Mexico

Mangoceuticals ($MGRX) Partners with Marius Pharmaceuticals: A Strategic Leap in Men's Health Market

Men's Telehealth Company's Plans To Change Men's Wellness

MangoRx Addresses $49.3 Billion Global GLP-1 Market With Launch of Oral Semaglutide for Advanced Weight Loss Treatment

Shares of Healthcare Company Rise Following Product Availability Announcement

BITF

BLUE

CHPT

GOTU

INVZ

LCID

MMAT

NKLA

OPEN

SIRI

Chanson International Holding - Class A Ordinary Shares

Chanson International

China Jo-Jo Drugstores, Inc. - Ordinary Shares

China Jo-Jo Drugstores

Dada Nexus Limited - American Depositary Shares

Dada Nexus

Davis Commodities Limited - Ordinary Shares

Davis Commodities

Almacenes Exito S.A. American Depositary Share, each representing eight (8) Common Shares

Comments

Mangoceuticals

Noticias

Últimas noticias sobre Mangoceuticals (NASDAQ:MGRX) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL